Share-based Payment Arrangement, Expense of Vistagen Therapeutics, Inc. from 31 Mar 2015 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Vistagen Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2015 to 31 Dec 2025.
  • Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $1,096,000, a 1.5% increase year-over-year.
  • Vistagen Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $4,071,000, a 5.1% increase year-over-year.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $4,315,000, a 98% increase from 2023.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,182,000, a 35% decline from 2022.
  • Vistagen Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $3,337,000, a 4.1% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Vistagen Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $4,071,000 $1,096,000 +$16,000 +1.5% 01 Oct 2025 31 Dec 2025 10-Q 12 Feb 2026 2026 Q3
Q3 2025 $4,055,000 $1,096,000 -$16,000 -1.4% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2026 Q2
Q2 2025 $4,071,000 $916,000 -$244,000 -21% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2026 Q1
Q1 2025 $4,315,000 $963,000 +$441,000 +84% 01 Jan 2025 31 Mar 2025 10-K 17 Jun 2025 2025 FY
Q4 2024 $3,874,000 $1,080,000 +$573,000 +113% 01 Oct 2024 31 Dec 2024 10-Q 12 Feb 2026 2026 Q3
Q3 2024 $3,301,000 $1,112,000 +$528,000 +90% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2026 Q2
Q2 2024 $2,773,000 $1,160,000 +$591,000 +104% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2026 Q1
Q1 2024 $2,182,000 $522,000 -$80,000 -13% 01 Jan 2024 31 Mar 2024 10-K 17 Jun 2025 2025 FY
Q4 2023 $2,262,000 $507,000 -$239,300 -32% 01 Oct 2023 31 Dec 2023 10-Q 13 Feb 2025 2025 Q3
Q3 2023 $2,501,300 $584,000 -$447,800 -43% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2025 Q2
Q2 2023 $2,949,100 $569,000 -$387,900 -41% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2025 Q1
Q1 2023 $3,337,000 $602,000 -$800,000 -57% 01 Jan 2023 31 Mar 2023 10-K 11 Jun 2024 2024 FY
Q4 2022 $4,137,000 $746,300 +$22,500 +3.1% 01 Oct 2022 31 Dec 2022 10-Q 13 Feb 2024 2024 Q3
Q3 2022 $4,114,500 $1,031,800 +$267,300 +35% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2024 Q2
Q2 2022 $3,847,200 $956,900 +$366,500 +62% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2024 Q1
Q1 2022 $3,480,700 $1,402,000 +$911,800 +186% 01 Jan 2022 31 Mar 2022 10-K 28 Jun 2023 2023 FY
Q4 2021 $2,568,900 $723,800 -$6,600 -0.9% 01 Oct 2021 31 Dec 2021 10-Q 07 Feb 2023 2022 Q3
Q3 2021 $2,575,500 $764,500 +$353,600 +86% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q2
Q2 2021 $2,221,900 $590,400 -$84,200 -12% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q1
Q1 2021 $2,306,100 $490,200 01 Jan 2021 31 Mar 2021 10-K 23 Jun 2022 2022 FY
Q4 2020 $730,400 01 Oct 2020 31 Dec 2020 10-Q 10 Feb 2022 2022 Q3
Q3 2020 $410,900 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2022 Q2
Q2 2020 $674,600 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q1

Vistagen Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $4,315,000 +$2,133,000 +98% 01 Apr 2024 31 Mar 2025 10-K 17 Jun 2025 2025 FY
2023 $2,182,000 -$1,155,000 -35% 01 Apr 2023 31 Mar 2024 10-K 17 Jun 2025 2025 FY
2022 $3,337,000 -$143,700 -4.1% 01 Apr 2022 31 Mar 2023 10-K 11 Jun 2024 2024 FY
2021 $3,480,700 +$1,174,600 +51% 01 Apr 2021 31 Mar 2022 10-K 28 Jun 2023 2023 FY
2020 $2,306,100 -$1,514,700 -40% 01 Apr 2020 31 Mar 2021 10-K 23 Jun 2022 2022 FY
2019 $3,820,800 +$377,400 +11% 01 Apr 2019 31 Mar 2020 10-K 29 Jun 2021 2021 FY
2018 $3,443,400 +$1,099,200 +47% 01 Apr 2018 31 Mar 2019 10-K 29 Jun 2020 2020 FY
2017 $2,344,200 +$1,492,900 +175% 01 Apr 2017 31 Mar 2018 10-K 25 Jun 2019 2019 FY
2016 $851,300 -$3,190,100 -79% 01 Apr 2016 31 Mar 2017 10-K 26 Jun 2018 2018 FY
2015 $4,041,400 +$1,581,300 +64% 01 Apr 2015 31 Mar 2016 10-K 29 Jun 2017 2017 FY
2014 $2,460,100 01 Apr 2014 31 Mar 2015 10-K 24 Jun 2016 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.